Bank of Cyprus Oncology Center

Nicosia 2006

0 studies enrolling now · 3 studies all time

What they study most

First Line Non-Small Cell Lung Cancer, Malignant Melanoma, Neoplasms, Neoplasms

Studies at this site

• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol — Completed
• A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies — Completed